Original Research: Telmisartan plus Amlodipine in Patients with Moderate or Severe Hypertension: Results from a Subgroup Analysis of a Randomized, Placebo-Controlled, Parallel-Group, 4 × 4 Factorial Study

References

• . Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):69–75
   PubMed Web of Science ®Google Scholar
• . Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens (Greenwich). 2006;8(2):93–98
   PubMedGoogle Scholar
• . Fang J, Alderman MH, Keenan NL, Ayala C, Croft JB. Hypertension control at physicians' offices in the United States. Am J Hypertens. 2008;21(2):136–142
   PubMed Web of Science ®Google Scholar
• . Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation. 2008;117(7):905–914
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR,; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289(19):2560–2572
   PubMed Web of Science ®Google Scholar
• . Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drugs. 2007;7(6):413–22
   PubMed Web of Science ®Google Scholar
• . Düsing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin. 2006;22(8):1545–1553
   PubMed Web of Science ®Google Scholar
• . Nilsson PM. Optimizing the pharmacologic treatment of hypertension: BP control and target organ protection. Am J Cardiovasc Drugs. 2006;6(5):287–295
   PubMedGoogle Scholar
• . Tedesco MA, Natale F, Calabrò R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens. 2006;8(9):634–641
   PubMedGoogle Scholar
• . Saito F, Fujita H, Takahashi A,. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. Hypertens Res. 2007;30(1):39–47
   PubMed Web of Science ®Google Scholar
• . Egan BM. Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker. J Clin Hypertens. 2007;9(10):783–789
   Google Scholar
• . Weber MA, Bakris GL, Dahlöf B,. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007;16(1):13–19
   PubMed Web of Science ®Google Scholar
• . Ishimitsu T, Kobayashi T, Honda T,. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res. 2005;28(4):351–359
   PubMed Web of Science ®Google Scholar
• . Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Böger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol. 2007;50(4):367–371
   PubMed Web of Science ®Google Scholar
• . Poldermans D, Glazes R, Kargiannis S,. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29(2):279–289
   PubMed Web of Science ®Google Scholar
• . Croxtall JD, Keating GM. Irbesartan/hydrochlorothiazide: in moderate to severe hypertension. Drugs. 2008;68(10):1465–1472
   PubMed Web of Science ®Google Scholar
• . Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(1):11–25
   PubMed Web of Science ®Google Scholar
• . Sharma AM, Davidson J, Koval S, Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. 2007;6:2–8
   PubMed Web of Science ®Google Scholar
• . White WB, Murwin D, Chrysant SG, Koval SE, Davidai G, Guthrie R. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit. 2008;13(1):21–27
   PubMed Web of Science ®Google Scholar
• . Sharma A, Bagchi A, Kinagi SB, Sharma YK, Baliga VP, Bollmall C. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther. 2007;29(12):2667–2676
   PubMed Web of Science ®Google Scholar
• . Fogari R, Derosa G, Zoppi A. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens. 2007;20(4):417–422
   PubMed Web of Science ®Google Scholar
• . Littlejohn III T, Majul CR, Olvera R,. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens. In press
   Google Scholar
• . American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens. 1992;5(4 pt 1):207–209
   PubMed Web of Science ®Google Scholar
• . McInnes GT. Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl. 2005;23(1):S3–S8
   PubMedGoogle Scholar
• . Preston RA, Baltodano NM, Cienki J, Materson BJ. Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. J Hum Hypertens. 1999;13(4):249–255
   PubMed Web of Science ®Google Scholar
• . Norris K, Neutel JM. Emerging insights in the first-step use of antihypertensive combination therapy. J Clin Hypertens (Greenwich). 2007;9( suppl 5):5–14
   PubMedGoogle Scholar
• . Julius S, Kjeldsen SE, Weber M,; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031
   PubMed Web of Science ®Google Scholar
• . Fogari R, Zoppi A, Derosa G,. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21(3):220–224
   PubMed Web of Science ®Google Scholar
• . Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587–604
   PubMed Web of Science ®Google Scholar